6 simple questions to tell if a ‘finfluencer’ is more flash than cash 
Why a ‘rip-off’ degree might be worth the money after all – research study 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Disaster or digital spectacle? The dangers of using floods to create social media content 
Trump’s Inflation Claims Clash With Voters’ Cost-of-Living Reality 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
What’s the difference between baking powder and baking soda? It’s subtle, but significant 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Singapore Budget 2026 Set for Fiscal Prudence as Growth Remains Resilient 
Locked up then locked out: how NZ’s bank rules make life for ex-prisoners even harder 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Bubs Australia will manufacture and distribute Bubs’ Chinese-label goat milk infant formula in China according to new Chinese standards. under an agreement with Heilongjiang Ubeite Dairy Group (HUG).
The new standards will come into effect in February 2023 .
The “ultra-premium” infant formula has been specially developed for Chinese infants using easily-digestible A2 goat-milk protein, sn2 palmitate (OPO), lactoferrin prebiotics, and nucleotides.
HUG has started submission with the State Administration for Market Regulation (SAMR) to renew its registration in line with China’s new GB standards for exclusive use under the Bubs brand.
According to Kristy Carr, Bubs founder and CEO, they have built strong brand trust and loyalty with Chinese families through marketing and selling Bubs English label infant formula products via the crossborder eCommerce channel, which accounts for around 20 percent of total Chinese infant formula sales.
If approved by SAMR, the formula will give Bubs access to the remaining 80 percent of China’s $25.9 billion infant formula market.
Bubs will also enter into a joint venture agreement, where it will hold a 75 percent interest, with Zhitong Health Technology to distribute its Chinese label goat infant formula products.
Bubs Australia expects to launch its product in the second half of FY23, subject to receiving SAMR approval.
